The ADAPT trial, a large (n = 375) phase II, open-label, multicenter study specifically conducted in patients with HR+/HER2+ BC, compared 12-week regimens of T-DM1 with or without endocrine therapy vs. trastuzumab plus endocrine therapy [88]. Here, ERBB2 is linked to breast cancer.